Published Online:17 Jan 2012https://doi.org/10.4155/bio.11.304
Abstract
Recombinant therapeutic protein drugs have now been in clinical use for nearly three decades and have advanced considerably in complexity over this time period. Regulatory approvals of some early pioneering protein drugs did not require characterization of metabolism, but more recently regulatory expectations and guidance have appropriately evolved. Sponsors may now be expected to investigate metabolism of newer biologics as the structural complexity of proteins has increased markedly, particularly with the introduction of conjugated and modified proteins. This review discusses the value and need for metabolite characterization of some therapeutic proteins by presenting select examples. Regulatory expectations will undoubtedly evolve further with the development of other novel macromolecular biologic therapeutics based on modified nucleic acids, novel conjugated lipids and polysaccharides.
Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest
References
- 1 European Medicines Agency. ICH Guideline S6 (R1) – preclinical safety evaluation of biotechnology-derived pharmaceuticals (1998).
- 2 European Medicines Agency. Guideline on the Clinical Investigation of the Pharmacokinetics of Therapeutic Proteins. (2007).
- 3 Braeckman R. Pharmacokinetics and pharmacodynamics of peptide and protein drugs, in pharmaceutical biotechnology: an introduction for pharmacists and pharmaceutical scientists. Crommelin D, Sindelar R (Eds). Taylor & Francis, PA, USA 429 (2002).
- 4 Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther.84(5),548–558 (2008).▪▪ Detailed examples of monoclonal antibody disposition mechanisms.
- 5 Roach P. New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations. Clin. Pharmacokinet.47(9),595–610 (2008).
- 6 Potocka E, Baughman RA, Derendorf H. Population pharmacokinetic model of human insulin following different routes of administration. J. Clin. Pharmacol.51(7),1015–1024 (2010).
- 7 Duckworth WC, Hamel FG, Peavy DE. Hepatic metabolism of insulin. Am. J. Med.85(5A),71–76 (1988).
- 8 Heinemann LW. Pharmacokinetics and glucodynamics of insulin lispro. Drugs of Today34(Supplement C),23–36 (1998).
- 9 Goykhman S, Drincic A, Desmangles JC et al. Insulin glargine: a review 8 years after its introduction. Expert Opin. Pharmacother.10(4),705–718 (2009).
- 10 Kuerzel GU, Shukla U, Scholtz HE et al. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr. Med. Res. Opin.19(1),34–40 (2003).
- 11 US FDA. Pharmacology Review of Application 21–081, Hoechst Marion Roussel (insulin glargine). 7–10 (2000).
- 12 Kurtzhals P, Schaffer L, Sorensen A et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes49(6),999–1005 (2000).
- 13 Sommerfeld MR, Muller G, Tschank G et al.In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS One5(3),e9540 (2010).▪▪ Detailed in vitro characterization of glargine metabolites showing a reduced mitogenic profile relative to intact glargine.
- 14 Agin A, Jeandidier N, Gasser F et al. Glargine blood biotransformation: in vitro appraisal with human insulin immunoassay. Diabetes Metab.33(3),205–212 (2007).
- 15 Ehninger G, Schmidt AH, Putting insulin glargine and malignancies into perspective. Oncologist14(12),1169–1174 (2009).
- 16 US FDA. Pharmacology Review of Application 21–536, Novo Nordisk Pharmaceuticals (Insulin Detemir). 13–16 (2005).
- 17 Modi M, Fulton J, Buckmann D. Clearance of PEGylated (40 kDa) interferon alfa-2a (PEGASYS) is primarily hepatic (abstract). Hepatology32,371A (2000).
- 18 Herold DA, Keil K, Bruns DE. Oxidation of polyethylene glycols by alcohol dehydrogenase. Biochem. Pharmacol.38(1),73–76 (1989).
- 19 Shaffer CB, Critchfield FH, Nair JH 3rd. The absorption and excretion of a liquid polyethylene glycol. J. Am. Pharm. Assoc. Am. Pharm. Assoc.39(6),340–344 (1950).
- 20 Bendele A, Seely J, Richey C et al. Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol. Sci.42(2),152–157 (1998).
- 21 Beck A, Haeuw JF, Wurch T et al. The next generation of antibody–drug conjugates comes of age. Discov. Med.10(53),329–339 (2010).
- 22 Ducry L, Stump B. Antibody–drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug. Chem.21(1),5–13 (2010).
- 23 Okeley NM, Miyamoto JB, Zhang X et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody–drug conjugate. Clin. Cancer Res.16(3),888–897 (2010).
- 24 Teshima G, Hancock W, Canova-Davis E. Effect of deamidation and isoaspartate formation on the activity of proteins. In: Deamidation and Isoaspartate Formation in Peptides and Proteins. Aswad D (Ed.). CRC Press: Boca Raton, CA, USA, 259 (1995).
- 25 Katsila T, Siskos AP, Tamvakopoulos C. Peptide and protein drugs: the study of their metabolism and catabolism by mass spectrometry. Mass Spectrom. Rev. doi:10.1002/mas.20340 (2011) (Epub ahead of print).▪▪ Comprehensive review of metabolite studies conducted with small protein and peptide drugs.
- 26 Campbell JL, Le Blanc JC. Peptide and protein drug analysis by MS: challenges and opportunities for the discovery environment. Bioanalysis3(6),645–657 (2011).▪ Compares and contrasts the sensitivities of different sample preparation strategies for LC–MS-based approaches and provides a detailed comparison of different MS instruments.
- 27 Mesmin C, Fenaille F, Ezan E et al. MS-based approaches for studying the pharmacokinetics of protein drugs. Bioanalysis3(5),477–480 (2011).
- 28 Copley K, McCowen K, Hiles R et al. Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr. Drug Metab.7(4),367–374 (2006).
- 29 Thevis M, Thomas A, Schanzer W. Mass spectrometric determination of insulins and their degradation products in sports drug testing. Mass Spectrom. Rev.27(1),35–50 (2008).
- 30 Zhang CX, Weber BVJ, Thammavong et al. Identification of carboxyl-terminal peptide fragments of parathyroid hormone in human plasma at low-picomolar levels by mass spectrometry. Anal. Chem.78(5),1636–1643 (2006).
- 101 US FDA Drug Safety Communication: update to ongoing safety review of Lantus™ (insulin glargine) and possible risk of cancer. 2011. www.fda.gov/Drugs/DrugSafety/ucm239376.htm
- 102 Polyethylene glycols (WHO Food Additive Series 14). www.inchem.org/documents/jecfa/jecmono/v14je19.htm
- 103 US FDA. Pfizer voluntarily withdraws cancer treatment Mylotarg from US market 2010. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm216448.htm
